# Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Astrocytoma

> **NCT00841555** · PHASE1 · COMPLETED · sponsor: **Ohio State University Comprehensive Cancer Center** · enrollment: 9 (actual)

## Conditions studied

- Glioblastoma Multiforme/Anaplastic Astrocytoma

## Interventions

- **DRUG:** temozolomide
- **RADIATION:** Hypofractionated radiation therapy
- **RADIATION:** Intensity-modulated radiation therapy

## Key facts

- **NCT ID:** NCT00841555
- **Lead sponsor:** Ohio State University Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02-13
- **Primary completion:** 2013-02-13
- **Final completion:** 2014-11-25
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2018-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00841555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00841555, "Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Astrocytoma". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00841555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*